A gigantic "blazar" may have fired a beam of light-speed particles at our planet, creating a 2023 "ghost particle" detection.

The most energetic "ghost particle" neutrino ever detected may have been blasted at Earth by blazars, black hole engines that ...

For more than half a century, particle physicists have theorized the existence of a “glueball,” a particle made entirely of gluons. While the past few decades have produced some compelling candidates, ...

Scientists working at CERN’s Large Hadron Collider may be seeing the strongest hints yet of physics beyond the Standard Model — the decades-old theory that explains the fundamental particles and ...

BETHLEHEM, Pa., April 28 /PRNewswire/ -- Particle Sciences, Inc. today announced the appointment of Robert W. Lee, Ph.D. to the position of Vice President, Pharmaceutical Development. Dr. Lee joins ...

BETHLEHEM, Pa., June 22, 2011 /PRNewswire/ -- In a recent announcement by Neurelis, a proprietary intranasal formulation of diazepam (NRL-1) achieved positive clinical results in a Phase I ...

Scientists at Johns Hopkins Medicine say they used a form of magnetic imaging to track cell therapy injections commonly used ...

BETHLEHEM, Pa., March 5, 2012 -- BETHLEHEM, Pa., March 5, 2012 /PRNewswire/ -- Particle Sciences, Inc. (PSI), a leading pharmaceutical CRO, and Lyotropic Therapeutics ...

Precision medicine aims to transport therapeutic agents, such as molecules, proteins or RNA, to the exact place where they need to act within the body. One of the most promising strategies is the use ...

Add Popular Science (opens in a new tab) More information Adding us as a Preferred Source in Google by using this link indicates that you would like to see more of our content in Google News results.

Particle Sciences expects to have commercial manufacturing capabilities up and running at its Bethlehem, Pennsylvania, facility by the end of the year and intends to manufacture both sterile and ...

BETHLEHEM, Pa., June 22, 2011 /PRNewswire/ -- In a recent announcement by Neurelis, a proprietary intranasal formulation of diazepam (NRL-1) achieved positive clinical results in a Phase I ...